meta
|
evidence
oncology
Living systematic review and meta-analysis
locally advanced NSCLC - maintenance (M)
laNSCLC - M - all population
1
laNSCLC - M - EGFR mutant
immune chekpoint inhibitors
anti-PD-(L)1
durvalumab based treatment
durvalumab alone
versus all
vs non active control
vs placebo
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
EGM
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
durvalumab alone
title
placebo
title
PACIFIC, 2017 NCT02125461 laNSCLC - M - all population 476/237
Pathology:
laNSCLC - M - all population;
laNSCLC - M - all population
PACIFIC, 2017
durvalumab alone
1
T1
placebo
0
T0